The Hatch-Waxman Playbook: Paragraph IV Certifications, 180-Day Exclusivity, and the $467 Billion Generic Drug Race
Every major pharmaceutical patent war starts with a single form filed with the FDA. It is not a lawsuit. No […]
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next
How litigation patterns, settlement timelines, and competitive pressure in biologics are rewriting the industry’s talent map — and what that
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
Win the Specialty Pharmacy Contract Before the Drug Patent Expires: A Business Development Guide for Biopharma Commercial & Market Access Vendors
The Clock You Are Ignoring Every branded drug in the specialty channel has an expiration date that has nothing to
Win EU Drug Tenders Before the Patent Expires: A Business Development Guide for Biopharma Commercial & Market Access Vendors
The Patent Clock Is a Sales Calendar Every drug patent that expires is a starting gun, not a finish line.
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing.
There’s a certain genre of drug question that never goes out of style: “Can this thing I’m already taking also
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing. Read Post »
Stop the DIY Search: An Inadequate Drug Patent FTO Opinion Puts You at Risk of Willful Infringement
Courts can triple damages for willful infringement. A flawed freedom-to-operate search is not a defense — it is evidence you
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams
Unit price is the number everyone fights over. It’s also the number that matters least. Pharmaceutical procurement has a dirty
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams Read Post »
Drug Patent Term Extensions: How Pharma Turns Extra Time Into Billions
The Clock You Can Buy In the drug industry, time is not just money. It is the only thing that
Drug Patent Term Extensions: How Pharma Turns Extra Time Into Billions Read Post »
The Hatch-Waxman Playbook: How Generic Drugmakers Use Patent Litigation to Get to Market Early
Introduction: The Law That Reshaped American Medicine In 1984, a California congressman named Henry Waxman and a Utah senator named
